Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Open Access
- 16 August 2021
- journal article
- review article
- Published by Wiley in International Journal of Cancer
- Vol. 149 (12) , 1980-1996
Abstract
Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 people being diagnosed with MM per year. Whereas 5‐year survival after a diagnosis of MM has improved from 28% in 1975 to 56% in 2012, the disease remains essentially incurable. In this review, we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that has led to improvements in survival, including recent changes to diagnosis and therapies. Areas of unmet need include the management of patients with high‐risk MM, those with reduced performance status and those refractory to standard therapies. Ongoing research into the biology and early detection of MM as well as the development of novel therapies, such as immunotherapies, has the potential to influence MM practice in the future.Keywords
Funding Information
- Cancer Research UK (C1298/A8362)
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Myeloma UK
This publication has 242 references indexed in Scilit:
- Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based studyBlood, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cellsBlood, 2011
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyBlood, 2010
- Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significanceBlood, 2009
- Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in SwedenBlood, 2009
- Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health StudyBlood, 2009
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective studyBlood, 2009
- Patterns of hematologic malignancies and solid tumors among 37,838 first‐degree relatives of 13,896 patients with multiple myeloma in SwedenInternational Journal of Cancer, 2009
- Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myelomaBlood, 2008